Tricida (TCDA) Stock Price, News & Analysis

Company Overview

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.11 to $0.19
• 52-Week Range: N/A
• Volume: 31.13 million shs
• Average Volume: 17.62 million shs
• Market Capitalization: $6.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Tricida Stock Analysis - MarketRank™

Tricida scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Tricida.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tricida are expected to grow in the coming year, from ($2.04) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tricida is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tricida is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TCDA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tricida does not currently pay a dividend.

Dividend Growth

Tricida does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.90

Short Interest

There is no current short interest data available for TCDA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for TCDA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tricida insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.60% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.

TCDA Stock Analysis - Frequently Asked Questions

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) released its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.09.

When did Tricida IPO?

Tricida (TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tricida investors own include Sorrento Therapeutics (SRNE), Alibaba Group (BABA), NIO (NIO), Pfizer (PFE), Energy Transfer (ET), Teladoc Health (TDOC) and Sesen Bio (SESN).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 7/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TCDA
• CIK: 1595585
• Web: www.tricida.com
• Phone: (415) 429-7800
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$176.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -103.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.87
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,670,000
• Free Float: 35,851,000
• Market Cap: $6.01 million
• Optionable: Not Optionable
• Beta: 0.22